Age and complexity no barrier to DES benefit

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1644, 2008-01, pp. : 12-12

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Age no barrier for chemotherapy in colorectal cancer

Inpharma, Vol. 1, Iss. 1310, 2001-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

In Vitro Modeling of the Blood-Brain Barrier: Simplicity Versus Complexity

Current Pharmaceutical Design, Vol. 17, Iss. 26, 2011-09 ,pp. : 2755-2761

Bentham Science Publishers

Access to resources Recommend Favorite

A Preliminary Benefit-Risk Assessment of Verteporfin in Age-Related Macular Degeneration

By Wickens Jason Blinder Kevin J.

Drug Safety, Vol. 29, Iss. 3, 2006-01 ,pp. : 189-199

Adis International

Access to resources Recommend Favorite

Drug Trials and Older People: Time to Embrace the Complexity of Age

By Witham Miles D.

Drugs & Aging, Vol. 28, Iss. 8, 2011-08 ,pp. : 679-680

Adis International

Access to resources Recommend Favorite

Age does not appear to be a barrier to aggressive therapy with paclitaxel and carboplatin in women with ovarian cancer

Inpharma, Vol. 1, Iss. 1224, 2000-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite